on ABL DIAGNOSTICS (EPA:ABLD)
ABL Diagnostics Transitions to ABL Texcell Diagnostics
ABL Diagnostics has officially rebranded to ABL Texcell Diagnostics following a decision by shareholders during an Extraordinary General Meeting on September 17, 2026. The change reflects the company's evolution, particularly in molecular diagnostics, virology, and life sciences. Despite considering a move to Euronext Growth Paris, shareholders opted to maintain the company's listing on the Euronext Paris regulated market. CEO Dr. Chalom B. Sayada stated that this platform is the most appropriate for supporting the company's growth and shareholder interests.
The rebranding aligns with ABL Texcell Diagnostics' commitment to advance its strategic roadmap. This includes expanding its activities and maintaining focus on molecular diagnostics and virology. The company aims to enhance investor visibility, improve share liquidity, and broaden its shareholder base while adhering to the standards of the regulated market. ABL Texcell Diagnostics plans to sustain its trajectory of profitable growth under the new identity.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABL DIAGNOSTICS news